Ms. Zhou, aged 54, was appointed as an executive Director of the Company on 15 July 2024. She is also the members of the Investment Appraisal Committee and the Nomination Committee of the Company.

She is a vice president and chief financial officer of Shanghai Pharmaceuticals Holding Co., Ltd. (Stock Exchange stock code: 2607, SSE stock code: 601607). She obtained a Master’s degree in Accounting from the Chinese University of Hong Kong and holds the title of economist. Ms. Zhou has nearly 30 years of financial and investment experience, having worked in investment banks in China, and has spent the last 20 years mainly in investment and corporate management work within Shanghai Industrial Investment (Holdings) Company Limited (“SIIC”, a controlling shareholder of the Company). She successively worked in Shanghai SIIC Asset Management Co., Ltd., SIIC Management (Shanghai) Ltd., Shanghai Hu-Ning Expressway (Shanghai Section) Co., Ltd., Shanghai Luqiao Development Co., Ltd., SIIC and Shanghai SIIC Group Finance Co., Ltd. (“SIIC Finance”), involving various fields such as asset operation, investment management, expressway development and financial fund management, and possesses extensive industry knowledge and rich management experience. Ms. Zhou also used to be a director and general manager of SIIC Finance. In addition, Ms. Zhou also has extensive experience in IT team building, risk control and management, resource input and output, as well as the introduction and application of new technologies.